Bortezomib in the management of anti-NMDA receptor encephalitis

de Liyis, Bryan Gervais; Sutedja, Jane Carissa; Evananda, Maria Pramesthi Sabrina; Wibisono, Ledwin Meikel; Karuniamaya, Chrysanta Paramitha; Soetomo, Cindy Thiovany; Susilawathi, Ni Made

doi:10.1186/s41983-023-00765-w

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 2 In vivo studies of bortezomib

From: Bortezomib in the management of anti-NMDA receptor encephalitis

Dose	Administration method	Duration	Findings	Citation
1.3 mg/m²	Subcutaneous injection	On days 1, 4, 8, and 11	Deficits of clinical features (including ataxia and dysarthria) and decreased serum anti-NMDA receptor antibody titers, with no adverse effect	[85]
1.3 mg/m²	Subcutaneous injection	On days 1, 4, 14, 25	Fast improvement on neurological deficits and decreased serum anti-NMDA receptor antibody titers	[91]
1.3 mg/m²	Subcutaneous injection	4 doses repeated weekly from day 147	Remarkable improvement on neurological deficits, regained sufficient respiratory function, and spontaneous eye opening	[83]
1.3 mg/m²	Intravenous injection	Two cycles 4 doses every 3 days	Progressive improvement in consciousness, clinical improvement with resolution of the status epilepticus, and persistent negative serum anti-NMDA receptor antibody titers	[92]
1.3 mg/m²	Subcutaneous injection	On days 40, 43, 47, and 50	Remarkable recovery with no drug tolerability issues and decreased serum anti-NMDA receptor antibody titers	[32]
1.3 mg/m²	Subcutaneous injection	On days 1, 4, 8, and 11 followed with 10 day rest before the second cycle	Significant improvement in cognitive function; disappearance of symptoms, including seizures, hallucinations, and involuntary movement; and declined serum anti-NMDA receptor antibody titers with no side effects found	[93]
1.3 mg/m²	Subcutaneous injection	On days 1, 4, 8, and 11 of a 21 day cycle for three cycles	Significant neurological recovery and repeated negative results of serum anti-NMDA receptor antibody titers	[94]
1.3 mg/m²	Subcutaneous injection	Five doses	Clinical improvement, including improvement in daily activities and reduced level of serum anti-NMDA receptor antibody titers	[94]
1.3 mg/m²	Intravenous injection	On days 1, 4, 8, and 11 for four cycles	Significant decreased of serum anti-NMDA receptor antibody titers, moderate dysarthria, and progressive consciousness	[95]
1.3 mg/m²	Intravenous injection and subcutaneous injection	On days 1, 4, 8, and 11 of a 21 day cycle for five cycles IV and SC on the sixth cycle	Improvement in daily activities and reduced level of serum anti-NMDA receptor antibody titers	[96]
1.3 mg/m²	Subcutaneous injection	Six cycles in 4 months	Gradual improvement in autonomic function and oro-lingual–facial dyskinesias and improvement in daily activities	[82]

NMDA N-methyl-d-aspartate

Back to article page